Sun Pharma shares rise as USFDA clears Mohali facility

Sun Pharma shares closed at Rs 708.25 per piece on BSE, up Rs 24 or 3.61%. 

Sun Pharma said, “It's subsidiaries or associate was informed by the US FDA yesterday, that it will lift the import alert imposed on the Mohali (Punjab) manufacturing facility and remove the facility from the official action initiated (OAI) status." 

The company further said, “This proposed action will clear the path for Sun Pharma to supply approved products from the Mohali facility to the US market, subject to normal US FDA regulatory requirements.”